| 3.42 -0.02 (-0.58%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.46 | 1-year : | 5.21 |
| Resists | First : | 3.81 | Second : | 4.46 |
| Pivot price | 3.1 |
|||
| Supports | First : | 3.01 | Second : | 2.51 |
| MAs | MA(5) : | 3.4 |
MA(20) : | 3.1 |
| MA(100) : | 3.69 |
MA(250) : | 2.09 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 84.6 |
D(3) : | 85.8 |
| RSI | RSI(14): 55.5 |
|||
| 52-week | High : | 5.57 | Low : | 0.37 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MYO ] has closed below upper band by 19.9%. Bollinger Bands are 21.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.44 - 3.46 | 3.46 - 3.48 |
| Low: | 3.25 - 3.27 | 3.27 - 3.29 |
| Close: | 3.38 - 3.42 | 3.42 - 3.45 |
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Mon, 22 Apr 2024
Myomo Inc. Revenue Breakdown – AMEX:MYO – TradingView - TradingView
Thu, 28 Mar 2024
Myomo Inc Enhances Board with Expert Heather Getz - TipRanks.com - TipRanks
Thu, 07 Mar 2024
Myomo, Inc. (MYO) Q4 2023 Earnings Call Transcript - Seeking Alpha
Thu, 07 Mar 2024
Myomo Reports Fourth Quarter and Full Year 2023 Financial Results - Business Wire
Thu, 07 Mar 2024
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Wed, 17 Jan 2024
Myomo to raise $6M with eyes on Medicare coverage - Mass Device
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 27 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 13.8 (%) |
| Held by Institutions | 47.9 (%) |
| Shares Short | 236 (K) |
| Shares Short P.Month | 298 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.41 |
| Profit Margin | -42.5 % |
| Operating Margin | -39.9 % |
| Return on Assets (ttm) | -34.4 % |
| Return on Equity (ttm) | -83.4 % |
| Qtrly Rev. Growth | 28 % |
| Gross Profit (p.s.) | 0.38 |
| Sales Per Share | 0.69 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -6.98 |
| PEG Ratio | 35.1 |
| Price to Book value | 8.14 |
| Price to Sales | 4.89 |
| Price to Cash Flow | -14.45 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|